Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial

Byung Ha Chung¹, Jian Huang², Zhang-Qun Ye³, Da-Lin He⁴, Hirotsugu Uemura⁵, Gaku Arai⁶, Choung Soo Kim⁷, Yuan-Yuan Zhang⁸, Yusoke Koroki⁹, SuYeon Jeong¹⁰, Suneel Mundle¹¹, Spyros Triantos¹², Sharon McCarthy¹³, Kim N Chi¹⁴, Ding-Wei Ye^15
1 Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 135-271, Korea Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China Wuhan Tongji Hospital, Tongji Medical College, Wuhan 430030, China First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 719054, China Kindai University Hospital, Ōsakasayama 589-8511, Japan Dokkyo Medical University Saitama Medical Center, Saitama 2-1-50, Japan Asian Medical Center, University of Ulsan, Seoul 138-040, Korea Janssen Medical Affairs Department, Beijing 100025, China Janssen Medical Affairs Department, Tokyo 101-0065, Japan Janssen Medical Affairs Department, Seoul 140-012, Korea Janssen Global Medical Affairs Department, Horsham, PA 08869, USA Janssen Research and Development, Spring House, PA 19477, USA Janssen Research and Development, Raritan, NJ 08869, USA BC Cancer and Vancouver Prostate Centre, Vancouver, BC V5Z 1G1, Canada Fudan University Shanghai Cancer Center, Shanghai 200032, China

Correspondence Address:
Ding-Wei Ye
Fudan University Shanghai Cancer Center, Shanghai 200032
China

Source of Support: None, Conflict of Interest: None

Check

1

DOI: 10.4103/aja.aja_64_21